Nasus Pharma (NSRX) Liabilities and Shareholders Equity (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Liabilities and Shareholders Equity came in at $5.0 million in Q4 2025, up 597.91% YoY from $717000.0 in Q4 2024, and up 683.1% on a QoQ basis from $639000.0 in Q2 2025.
Nasus Pharma (NSRX) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $5.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Nasus Pharma | 32.04 Mn | 32.04 Mn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 Mn |
| Jun 30, 2025 | 639,000.00 |
| Dec 31, 2024 | 717,000.00 |